More than 11,000 bottles of chlorthalidone were recalled over a dissolving failure.
More than 11,000 bottles of a common blood pressure medication have been recalled nationwide after laboratory testing found the tablets may not dissolve properly in the body, raising concerns about whether patients taking the drug are receiving its full intended effect.
The recall covers specific lots of chlorthalidone, a prescription diuretic used to treat high blood pressure and fluid retention. The affected tablets were manufactured by Inventia Healthcare Limited, based in Mumbai, India, and distributed across the United States by Rising Pharma Holdings of East Brunswick, New Jersey.
Why chlorthalidone was pulled from circulation
Inventia Healthcare initiated the voluntary recall on June 5 after testing revealed certain lots failed what the pharmaceutical industry calls dissolution specifications. Dissolution testing measures how quickly and completely a tablet breaks down in liquid to release its active ingredients. When a drug fails this standard, there is no assurance the medication is delivering the dose the patient needs. For a blood pressure drug taken to manage a chronic condition, that gap in performance carries real health consequences.
On June 22, the FDA classified the recall as a Class II action, designating it a moderate hazard. This classification applies when a recalled product’s use could lead to temporary or medically reversible health effects. It falls below Class I, which is reserved for products posing potentially life-threatening risks, and above Class III, which covers labeling errors and non-health-threatening issues.
How to check if your chlorthalidone prescription is affected
The recall applies to 25-milligram chlorthalidone tablets sold in both 100-count and 1,000-count bottles. The affected 100-count bottles carry batch code RISA24001, while the 1,000-count bottles carry batch code RISB24002. Both have an expiration date of April 2027. Patients can verify whether their medication matches the recalled product by checking the batch number printed on the label.
The FDA has not yet issued specific instructions for patients holding affected bottles. Anyone who believes their prescription matches the recalled product should contact their prescribing physician or pharmacist before making any changes to their medication routine. Stopping blood pressure medication without medical guidance can cause serious complications, according to the American Heart Association, and any switch to a replacement prescription should happen under a doctor’s supervision.
What chlorthalidone does and why the recall matters
Chlorthalidone is prescribed to treat hypertension and to reduce fluid buildup associated with heart, kidney or liver conditions. The drug works by prompting the kidneys to remove excess water and salt from the body through urine, lowering the fluid volume putting pressure on blood vessel walls. A tablet that fails to dissolve correctly is effectively a missed dose for a patient relying on consistent daily treatment.
High blood pressure is one of the most common chronic conditions in the United States, making diuretics like chlorthalidone among the most widely prescribed medications in the country.
A second blood pressure recall in under a year
This is the second recall of a widely prescribed blood pressure medication in less than 12 months. In October 2025, more than 500,000 bottles of prazosin hydrochloride were pulled from shelves after testing revealed the capsules contained compounds linked to cancer at unsafe levels. The back-to-back recalls have intensified scrutiny of quality control standards in overseas pharmaceutical manufacturing facilities.
Patients with concerns about the recall can search the affected batch numbers directly on the FDA’s website or contact their pharmacy for guidance on next steps.
Source: Today.com